---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011987"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:39:36.771604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4

## Summary
- Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.
- FDA PDUFA date March 20, 2026 for setmelanotide in acquired hypothalamic obesity.
- Positive end-of-Phase-2 meeting with FDA for bivamelagon in acquired HO; Phase 3 trial to start by end of 2026.
- Cash and investments $388.9M at Dec 31, 2025; net loss $48.8M in Q4 2025 vs $44.6M in Q4 2024.
- Topline data expected March 2026 from Phase 3 EMANATE trial and Japanese cohort in acquired HO.

## SEC filing metadata
- accession: 0001628280-26-011987
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/0001628280-26-011987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011987
- JSON: https://secwatch.observer/filing/0001628280-26-011987.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.